Nano-Cap iBio Expands Obesity Program With New Antibody Using In-Licensed Platform iBio advances obesity treatment with IBIO-600, a long-acting anti-myostatin antibody designed for subcutaneous ...

Shares of iBio Inc. IBIO climbed 15.45% to $5.83 Friday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.63% to ...

SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio’s common stock has been approved for ...

Based on data from TipRanks, one Wall Street analyst has a Buy rating on the stock and a 12-month price forecast of $6. Moreover, three analysts have an average “Strong Buy” rating on Ibio ...

Short interest in iBio Inc (NASDAQ:IBIO ... of this short interest to close out their positions without sending the stock sharply higher.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on IBIO: ...

Shares of iBio Inc. IBIO soared 34.31% to $5.05 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 2.78% to ...

today announced that iBio’s common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American.

In this article, we are going to take a look at where Ibio, Inc. (NYSEAMERICAN ... this year we used Insider Monkey’s insider trading stock screener and looked for stocks with at least five ...

The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented,“We ...